Development of gelatin nanoparticles for positron emission tomography diagnosis in pancreatic cancer-Reference-Cited by-同舟云学术

Development of gelatin nanoparticles for positron emission tomography diagnosis in pancreatic cancer

Published:2024-09-03 Issue: Volume: Page:
ISSN:0033-8230
Container-title:Radiochimica Acta
language:en
Short-container-title:

Author:

Sugo Yumi¹,Kimura Atsushi¹^ORCID,Koizumi Tomoya²,Oyama Kotaro¹^ORCID,Taguchi Mitsumasa¹²^ORCID

Affiliation:

1. Takasaki Institute for Advanced Quantum Science , National Institutes for Quantum Science and Technology (QST) , 1233 Watanuki-machi , Takasaki , Gunma , 370-1292 Japan

2. Graduate School of Science and Technology , Gunma University , 1-5-1 Tenjintyo , Kiryu , Gunma , Japan

Abstract

Abstract Pancreatic cancer remains difficult to diagnose using currently available imaging probes. Thus, this study aimed to develop a novel imaging agent for the diagnosis of pancreatic cancer using positron emission tomography (PET). Specifically, this study explores gelatin-based nanoparticles fabricated via radiation-induced crosslinking, as gelatin is known for its ability to produce biocompatible materials. Aqueous gelatin solutions were irradiated with γ-rays to produce nanoparticles with average diameters of 5–20 nm via a radiation crosslinking technique. The gelatin nanoparticles were labeled with 64Cu, exhibiting negative surface potentials. Furthermore, the nanoparticles were evaluated in vivo by injecting them into pancreatic tumor-bearing mice. Notably, the nanoparticles accumulated in the tumors. Hence, 64Cu-labeled gelatin nanoparticles show promise as a platform for next-generation PET imaging agents for pancreatic cancer.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/ract-2024-0304/pdf

Reference57 articles.

1. Dayton, P. A.; Ferrara, K. W. Targeted Imaging Using Ultrasound. J. Magn. Reson. Imag. 2002, 16, 362–377; https://doi.org/10.1002/jmri.10173.

2. Terreno, E.; Castelli, D. D.; Viale, A.; Aime, S. Challenges for Molecular Magnetic Resonance Imaging. Chem. Rev. 2010, 110, 3019–3042; https://doi.org/10.1021/cr100025t.

3. Torigian, D. A.; Huang, S. S.; Houseni, M.; Alavi, A. Functional Imaging of Cancer with Emphasis on Molecular Techniques. CA Cancer J. Clin. 2007, 57, 206–224; https://doi.org/10.3322/canjclin.57.4.206.

4. Zhu, L.; Ploessl, K.; Kung, H. F. PET/SPECT Imaging Agents for Neurodegenerative Diseases. Chem. Soc. Rev. 2014, 43, 6683–6691; https://doi.org/10.1039/c3cs60430f.

5. Lisney, A. R.; Leitsmann, C.; Strauß, A.; Meller, B.; Bucerius, J. A.; Sahlmann, C. O. The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer–A Practical Clinical Review. Cancers 2022, 14, 3638; https://doi.org/10.3390/cancers14153638.